SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $728,383 | -31.3% | 50,177 | -1.0% | 0.00% | – |
| Q2 2023 | $1,060,879 | +73.2% | 50,687 | +74.7% | 0.00% | – |
| Q1 2023 | $612,648 | +13.2% | 29,008 | +36.4% | 0.00% | – |
| Q4 2022 | $541,067 | +17.1% | 21,260 | +10.6% | 0.00% | – |
| Q3 2022 | $462,000 | +37.5% | 19,216 | +10.0% | 0.00% | – |
| Q2 2022 | $336,000 | +44.8% | 17,472 | +30.7% | 0.00% | – |
| Q1 2022 | $232,000 | -15.0% | 13,365 | +7.0% | 0.00% | – |
| Q4 2021 | $273,000 | +14.2% | 12,493 | 0.0% | 0.00% | – |
| Q3 2021 | $239,000 | +174.7% | 12,493 | +147.7% | 0.00% | – |
| Q2 2021 | $87,000 | -29.8% | 5,043 | -8.9% | 0.00% | – |
| Q1 2021 | $124,000 | +34.8% | 5,535 | +34.1% | 0.00% | – |
| Q4 2020 | $92,000 | +87.8% | 4,129 | +24.3% | 0.00% | – |
| Q3 2020 | $49,000 | -25.8% | 3,322 | -25.3% | 0.00% | – |
| Q2 2020 | $66,000 | +61.0% | 4,446 | +18.7% | 0.00% | – |
| Q1 2020 | $41,000 | +7.9% | 3,747 | -12.9% | 0.00% | – |
| Q4 2019 | $38,000 | +46.2% | 4,300 | +22.4% | 0.00% | – |
| Q3 2019 | $26,000 | -21.2% | 3,513 | 0.0% | 0.00% | – |
| Q2 2019 | $33,000 | +153.8% | 3,513 | +37.0% | 0.00% | – |
| Q1 2019 | $13,000 | +18.2% | 2,565 | 0.0% | 0.00% | – |
| Q4 2018 | $11,000 | -47.6% | 2,565 | 0.0% | 0.00% | – |
| Q3 2018 | $21,000 | +16.7% | 2,565 | 0.0% | 0.00% | – |
| Q2 2018 | $18,000 | -45.5% | 2,565 | +10.8% | 0.00% | – |
| Q1 2018 | $33,000 | +65.0% | 2,315 | 0.0% | 0.00% | – |
| Q4 2017 | $20,000 | -25.9% | 2,315 | 0.0% | 0.00% | – |
| Q3 2017 | $27,000 | +80.0% | 2,315 | +109.1% | 0.00% | – |
| Q2 2017 | $15,000 | 0.0% | 1,107 | 0.0% | 0.00% | – |
| Q1 2017 | $15,000 | +87.5% | 1,107 | 0.0% | 0.00% | – |
| Q4 2016 | $8,000 | – | 1,107 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |